On October 7, C.H. Robinson fell 5.08% in regular trading at $133.41 per share, with turnover of $205 million.

The decline reflects market concerns about financing the $5.8 billion acquisition of RXO, along with JPMorgan's decision to cut its price target on the stock from $225 to $198, a 12% reduction. The cash-and-stock deal values RXO at $17.25 per share, raising questions about integration costs and short-term pressure on C.H. Robinson's balance sheet.

Despite the move, some analysts see strategic advantages. UBS said the tie-up could help the combined company meaningfully widen its competitive gap, with projected EPS accretion of $1.15 at the midpoint and a 2028 EPS outlook lifted from $9.20 to $10.35. The reaction highlights how transaction risk is dominating sentiment even when the long-term rationale appears intact.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)